Immix Biopharma, Common Stock (id:5975 IMMX)
1.79 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 3:36:09 PM)
Exchange closed, opens in 1 day 17 hours
5.92 USD (5.92%)
11.18 USD (11.18%)
30.66 USD (30.66%)
-26.64 USD (-26.64%)
-62.47 USD (-62.47%)
-64.20 USD (-64.20%)
About Immix Biopharma, Common Stock
Market Capitalization 47.21M
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
| Headquarters (address) |
11400 West Olympic Boulevard Los Angeles 90064 CA United States |
| Phone | 310 651 8041 |
| Website | https://www.immixbio.com |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | IMMX |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.26 - 7.75 |
| Market Capitalization | 47.21M |
| P/E trailing | -2.01 |
| P/E forward | -3.13 |
| Price/Book | 1.97 |
| Beta | 0.104 |
| EPS | -0.830 |
| EPS United States (ID:6, base:3402) | 24.25 |